Sensus Healthcare, Inc. logo

Sensus Healthcare, Inc.

SRTS

NASDAQHealthcareMedical - Devices

Previous close

$3.34

+$0.11 · +3.41%

Aug 21, 4:00 PM ET

SRTS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

57

Fair Value

Momentum

26

Weakening

Sentiment

72

Bullish

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Joseph C. Sardano
Listed since
Jul 26, 2016
Employees
60

Market position

Day range

Current $3.34

52-week range

Current $3.34

Open
$3.29
Previous close
$3.23
Volume
24.63K
0.51× average
Average volume
48.72K
Average daily volume
Market cap
54.98M USD
Beta
1.12
Market reference 1
50-day average
$2.9775
+12.17% above average
200-day average
$3.7916
-11.91% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
43.58M USD
P/E (TTM)
-3.56×
P/B (TTM)
1.49×
P/S (TTM)
3.14×
EV / EBITDA
-4.72×
Earnings yield
-11.88%
Free cash flow yield
0.51%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
36.39%
Operating margin
-75.72%
Net margin
-88.45%
Return on equity
-16.05%
Return on assets
-14.55%
Return on invested capital
-17.02%

Financial health

Debt / equity
0.01×
Current ratio
9.72×
Altman Z-score
7.92
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends77%35%-6%-48%Gross margin, FY2021: 62.82%Gross margin, FY2022: 66.53%Gross margin, FY2023: 57.61%Gross margin, FY2024: 58.44%Gross margin, FY2025: 43.18%Operating margin, FY2021: 15.24%Operating margin, FY2022: 33.30%Operating margin, FY2023: -1.57%Operating margin, FY2024: 19.35%Operating margin, FY2025: -37.50%Net margin, FY2021: 15.23%Net margin, FY2022: 54.44%Net margin, FY2023: 1.99%Net margin, FY2024: 15.90%Net margin, FY2025: -28.09%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 62.82%. Gross margin FY2022 66.53%. Gross margin FY2023 57.61%. Gross margin FY2024 58.44%. Gross margin FY2025 43.18%. Operating margin FY2021 15.24%. Operating margin FY2022 33.30%. Operating margin FY2023 -1.57%. Operating margin FY2024 19.35%. Operating margin FY2025 -37.50%. Net margin FY2021 15.23%. Net margin FY2022 54.44%. Net margin FY2023 1.99%. Net margin FY2024 15.90%. Net margin FY2025 -28.09%.

Income trends

Revenue

27.48M USD-34.26%

Operating income

−10.31M USD−18.4M USD

Net income

−7.72M USD−14.37M USD
Income trends across reported periods50.02M USD28.08M USD6.14M USD−15.79M USDRevenue, FY2021: 27.04M USDRevenue, FY2022: 44.53M USDRevenue, FY2023: 24.41M USDRevenue, FY2024: 41.81M USDRevenue, FY2025: 27.48M USDOperating income, FY2021: 4.12M USDOperating income, FY2022: 14.83M USDOperating income, FY2023: −382K USDOperating income, FY2024: 8.09M USDOperating income, FY2025: −10.31M USDNet income, FY2021: 4.12M USDNet income, FY2022: 24.24M USDNet income, FY2023: 485K USDNet income, FY2024: 6.65M USDNet income, FY2025: −7.72M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 27.04M USD. Revenue FY2022 44.53M USD. Revenue FY2023 24.41M USD. Revenue FY2024 41.81M USD. Revenue FY2025 27.48M USD. Operating income FY2021 4.12M USD. Operating income FY2022 14.83M USD. Operating income FY2023 −382K USD. Operating income FY2024 8.09M USD. Operating income FY2025 −10.31M USD. Net income FY2021 4.12M USD. Net income FY2022 24.24M USD. Net income FY2023 485K USD. Net income FY2024 6.65M USD. Net income FY2025 −7.72M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue27.48M USD41.81M USD24.41M USD44.53M USD27.04M USD
Cost of goods sold15.62M USD17.38M USD10.35M USD14.9M USD10.05M USD
Gross profit11.87M USD24.43M USD14.06M USD29.63M USD16.99M USD
Research and development7.78M USD4.22M USD3.68M USD3.46M USD3.44M USD
Selling, general, and administrative14.4M USD12.13M USD10.76M USD11.34M USD9.43M USD
Operating expenses22.17M USD16.34M USD14.44M USD14.8M USD12.87M USD
Interest income683K USD932K USD992K USD382K USD2K USD
Interest expense2K USD1K USD
Depreciation and amortization386K USD432K USD461K USD509K USD613K USD
Operating income−10.31M USD8.09M USD−382K USD14.83M USD4.12M USD
Net income−7.72M USD6.65M USD485K USD24.24M USD4.12M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-12.45%
11 comparable reports
Latest EPS result
-0.53
Estimate -0.13 · Miss by 324.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.15-0.09-0.34-0.58Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 0.09, estimate 0.1, surprise -10.00%, Miss. Q2 2025, reported May 15, 2025: actual -0.16, estimate 0.04, surprise -500.00%, Miss. Q3 2025, reported Aug 7, 2025: actual -0.06, estimate 0.01, surprise -700.00%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.06, estimate -0.11, surprise +45.45%, Beat. Q1 2026, reported Feb 12, 2026: actual -0.19, estimate -0.055, surprise -245.45%, Miss. Q2 2026, reported May 7, 2026: actual -0.16, estimate -0.125, surprise -28.00%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.53, estimate -0.125, surprise -324.00%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.055, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates13.93M9.93M5.94M1.95MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 13.07M USD, estimate 6.35M USD, surprise +105.61%, Beat. Q2 2025, reported May 15, 2025: actual 8.34M USD, estimate 7.23M USD, surprise +15.34%, Beat. Q3 2025, reported Aug 7, 2025: actual 7.32M USD, estimate 6.31M USD, surprise +15.88%, Beat. Q4 2025, reported Nov 6, 2025: actual 6.88M USD, estimate 6.31M USD, surprise +9.05%, Beat. Q1 2026, reported Feb 12, 2026: actual 4.94M USD, estimate 8.35M USD, surprise -40.81%, Miss. Q2 2026, reported May 7, 2026: actual 3.39M USD, estimate 5.32M USD, surprise -36.24%, Miss. Q3 2026, reported Aug 13, 2026: actual 2.29M USD, estimate 4.6M USD, surprise -50.23%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 6.61M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$4.75

42.22% upside
Past 12 months12-month forecastHigh $5.50Average $4.75Low $4.00

Rating distribution

9 ratings
Strong buy00%
Buy667%
Hold333%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions

SRTS news

SRTS peers

ETFs holding SRTS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research SRTS

research.disclaimer